Regulatory Approvals

NanoViricides Gains FDA Orphan Drug Designation for Measles Drug NV-387 Amid Global Outbreaks

NanoViricides Gains FDA Orphan Drug Designation for Measles Drug NV-387 Amid Global Outbreaks

NanoViricides received FDA Orphan Drug Designation for its broad-spectrum antiviral NV-387 to treat measles, offering incentives and supporting regulatory advancement as global cases rise.

May 4, 2026
NeuroOne to Host Investor Webinar Following Recent FDA Clearance

NeuroOne to Host Investor Webinar Following Recent FDA Clearance

NeuroOne Medical Technologies will hold a virtual investor webinar on October 7, 2025, to discuss business operations and recent FDA clearance, highlighting the company's progress in developing neurological disorder treatments.

September 29, 2025
Quantum BioPharma Receives Health Canada Product License for Qlarity Natural Health Product

Quantum BioPharma Receives Health Canada Product License for Qlarity Natural Health Product

Quantum BioPharma Ltd. has secured Health Canada approval for its Qlarity natural health product, expanding its market reach and revenue potential through regulatory clearance for cognitive and energy support supplements.

September 18, 2025